RAPT Therapeutics (RAPT) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAPT shares.
View RAPT analyst ratings or view top-rated stocks.

8 brokers have issued 1-year target prices for RAPT Therapeutics' shares. Their RAPT share price forecasts range from $23.00 to $48.00. On average, they anticipate the company's share price to reach $41.22 in the next year. This suggests a possible upside of 94.7% from the stock's current price.
View analysts price targets for RAPT or view top-rated stocks among Wall Street analysts.

RAPT Therapeutics' stock was trading at $19.80 at the beginning of 2023. Since then, RAPT stock has increased by 6.9% and is now trading at $21.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RAPT earnings forecast.

RAPT Therapeutics, Inc. (NASDAQ:RAPT) issued its earnings results on Tuesday, March, 14th. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.67) by $0.03.

ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Alger 35 ETF (ATFV), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Biotechnology ETF (IBB).

8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

(RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO.

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

RAPT Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (13.00%), Price T Rowe Associates Inc. MD (9.67%), Perceptive Advisors LLC (6.67%), BlackRock Inc. (6.33%), State Street Corp (4.77%) and Great Point Partners LLC (3.95%). Insiders that own company stock include Brian Russell Wong, Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends.

Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RAPT stock can currently be purchased for approximately $21.17.

RAPT Therapeutics (NASDAQ:RAPT) has a market capitalization of $727.19 million and generates $1.53 million in revenue each year. The company earns $-83,840,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rapt.com. The company can be reached via phone at (650) 489-9000 or via email at investors@rapt.com.